알림
뒤로
mobile background

항암 및 항암보조제

Oncology Portal | News
2021-01-30

https://pumabiotechnology.com/pr20201211_NALA.html

2021-01-30

https://pumabiotechnology.com/pr20201209_ExteNET.html

2021-01-30

https://pumabiotechnology.com/pr20201209_SUMMIT.html

2021-01-30

https://pumabiotechnology.com/pr20201117.html

2021-01-30

https://pumabiotechnology.com/pr20201105_SUMMIT.html

2021-01-30

https://pumabiotechnology.com/docs/101520_NCCNORP_Puma_Neratinib.pdf

2021-01-30

https://pumabiotechnology.com/pr20201005.html

2021-01-30

https://pumabiotechnology.com/pr20200819.html

2020-07-29

https://www.gynecologiconcology-online.net/article/S0090-8258(20)33660-X/fulltext

2020-07-29

https://www.businesswire.com/news/home/20200716005844/en/Puma-Biotechnology-Licensing-Partner-Specialised-Therapeutics-Receives

Copyright 2021 - BIXINK   │   Terms of Use

 Contact   │   Privacy

서울특별시 강남구 논현로 561 6층 [06125]

6F, 561 Nonhyeon-ro, Gangnam-gu, Seoul 06125, Republic of Korea

Copyright 2020 - BIXINK    |    Terms of Use    |    Contact

서울특별시 강남구 테헤란로 13길 8-11 7층 [06133]

7F, 8-11 Teheran-ro 13-gil , Gangnam-gu, Seoul 06133, Republic of Korea